Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

Sibylle Loibl,Dennis Rokitta,B. Conrad,Nadia Harbeck,Michaela Wüllner,Mathias Warm,Kathrin Schwedler,Bernd Gerber,Iris Schrader,Holger Eidtmann,Keyur Mehta,Uwe Fuhr,Gunter von Minckwitz

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

2014

Sibylle Loibl
Dennis Rokitta
B. Conrad
Nadia Harbeck
Michaela Wüllner
Mathias Warm
Kathrin Schwedler
Bernd Gerber
Iris Schrader
Holger Eidtmann
Keyur Mehta
Uwe Fuhr
Gunter von Minckwitz

Background: Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II stu

Keywords:

Taxane
Breast cancer
Gynecology
Phases of clinical research
Sorafenib
Anthracycline
Chemotherapy
Medicine
early breast cancer
neoadjuvant treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations